Differential Regulation of Lipoprotein Kinetics by Atorvastatin and Fenofibrate in Subjects With the Metabolic Syndrome

F. Watts, Gerald; Hugh R. Barrett, P.; Ji, Juying; Serone, Adrian; C. Chan, Dick; D. Croft, Kevin; Loehrer, F.; G. Johnson, Anthony

doi:10.2337/diabetes.52.3.803

Public

Differential Regulation of Lipoprotein Kinetics by Atorvastatin and Fenofibrate in Subjects With the Metabolic Syndrome

Published in Diabetes • Mar 1, 2003

Authors:

Gerald F. Watts

P. Hugh R. Barrett

Juying Ji

Abstract

The metabolic syndrome is characterized by insulin resistance and abnormal apolipoprotein AI (apoAI) and apolipoprotein B-100 (apoB) metabolism that may collectively accelerate atherosclerosis. The effects of atorvastatin (40 mg/day) and micronised fenofibrate (200 mg/day) on the kinetics of apoAI a...

Subject

Fenofibrate

Apolipoprotein B

Internal medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!